Company overview
KBI Biopharma is a global CDMO providing end-to-end biologics development and manufacturing, from cell line development to commercial cGMP supply. They specialize in complex molecules like mAbs, Fc-fusions, multispecifics, and conjugates using platforms such as SUREtechnology Platform™ and PUREplatform™. Capabilities include advanced analytical characterization, process development, formulation, and state-of-the-art facilities with 10 x 2,000L single-use bioreactors.
KBI Biopharma is listed in the NovaPharmaNews Supplier Hub as a CDMO & Manufacturing partner serving United States & Americas. Core focus areas include kbi biopharma, biologics cdmo, cgmp manufacturing, cell line development, analytical services.
Industry categories: CDMO & Manufacturing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Products and technologies associated with KBI Biopharma include Cdmo — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://www.kbibiopharma.com
- Categories
- CDMO & Manufacturing
- Markets served
- United States & Americas
- Keywords
- kbi biopharma, biologics cdmo, cgmp manufacturing, cell line development, analytical services
Products & technologies
Therapeutic areas
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What biologics development and manufacturing capabilities does KBI Biopharma offer?
- KBI provides comprehensive services from cell line development, process and analytical development, formulation, to clinical and commercial cGMP manufacturing for complex molecules including mAbs, multispecifics, and conjugates.
- What regulatory standards does KBI Biopharma comply with?
- KBI adheres to cGMP standards for preclinical, clinical, and commercial supply of therapeutics and vaccines, with reliable manufacturing processes developed in-house or transferred from clients.
- What are KBI Biopharma's manufacturing facilities and capacities?
- Facilities include 10 x 2,000L single-use bioreactors for mammalian processes and a 2,000L fermenter for microbial, supporting high-titer production across clinical and commercial scales.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
